Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 24, 2006. The report serves to disclose details regarding the appointment of Dr. Monsif Slaoui to the Board of Directors, effective May 17, 2006, in compliance with the Financial Services Authority's Listing Rules.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a corporate governance disclosure and does not contain financial performance data.
Material Changes
The material change disclosed is the appointment of Dr. Monsif Slaoui as an Executive Director. The filing clarifies that Dr. Slaoui has not served as a director of a publicly quoted company in the past five years.
Management Commentary and Disclosures
Management provided specific details regarding Dr. Slaoui's shareholdings as of the filing date:
- Ordinary Shares: 38,820 shares acquired prior to appointment.
- Share Options: Interest in 134,500 shares (direct and indirect via spouse) granted prior to appointment.
- Share Value Plan: 5,860 shares granted prior to appointment.
- Performance Share Plan: 59,163 shares granted prior to appointment.
Dr. Slaoui has no details to disclose regarding paragraphs 9.6.13 R (2) to (6) of the Financial Services Authority's Listing Rules.
Investor Verification Checklist
- Verify the effective date of Dr. Slaoui's board appointment (May 17, 2006).
- Confirm the total number of share interests held by Dr. Slaoui across all plans.
- Note that this filing contains no financial results; refer to Form 20-F for financial data.